<?xml version="1.0" encoding="UTF-8"?>
<p>A major question within the regulatory approval phase is to consider if a risk management plan, as a post-approval follow-up, has to be put in place at the moment of the MA (
 <xref rid="B29" ref-type="bibr">29</xref>). Looking into the level of evidence provided by most of the regulatory procedures previously adopted, we would consider it as absolutely necessary. A low level of evidence, available for comparability and eventual interchangeability, leads to inadequate safety guarantees to protect the patients.
</p>
